Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11632114 | 0.80 | — | — | |
| SCHEMBL21667349 | 0.80 | — | — | |
| SCHEMBL27992132 | 0.80 | TSHR (0.35) | TSHRSMN1; SMN2GRIK1GRIK2MAPT | |
| SCHEMBL1077419 | 0.78 | TSHR (0.46) | TSHRSMN1; SMN2GRIK1GRIK2MAPT | |
| SCHEMBL22750295 | 0.74 | TGFBR1 (0.43) | TSHRSMN1; SMN2 | |
| SCHEMBL7535185 | 0.70 | DDAH1 (0.31) | ALDH1A1 | |
| SCHEMBL8956995 | 0.69 | TSHR (0.38) | TSHRALDH1A1FGFR4 | |
| SCHEMBL170265 | 0.67 | — | — | |
| SCHEMBL4243337 | 0.67 | — | — | |
| SCHEMBL16792799 | 0.67 | CTSK (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1509274-A | Metallo proteinase inhibitors | — | 2004-06-30 | — | — | CN | claimed |
| US-20040110809-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | US | claimed |
| CN-1509274-A | Metallo proteinase inhibitors | — | 2004-06-30 | — | — | CN | disclosed |
| US-20040110809-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110809-A1 | Metalloproteinase inhibitors | MMP9, MMP2, MMP3 | TSHR 3771/4885SMN1; SMN2 3091/4885GRIK1 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.